CXCL10 levels could be used as a significant marker for early discovery and application of therapeutic approaches to recover from and/or prevent diabetic peripheral neuropathy.

Earlier studies have depicted the function of chemokines in the progress of neuropathy and neuropathic pain disorders. This pilot study aimed to investigate the link between plasma concentrations of chemokines (CXCL9, CXCL10, and CXCL11) and the incidence of diabetic peripheral neuropathy (DPN) in diabetic patients.

Overall, 73 diabetic patients were studied. Thirty-six of these patients had DPN and 37 were without DPN. The Semmes-Weinstein test was used to determine DPN. The Duoset ELISA kits were used to determine the plasma levels of circulating chemokines.

CXCL10 levels were considerably elevated in individuals having DPN compared to individuals without DPN. Although not statistically significant, the serum levels of CXCL9 were also greater in DPN patients, as shown in Table 1: 

Enhanced circulating levels of CXCL10 were found to be linked with DPN, proposing a role of this particular chemokine in the development of DPN.